Source:http://linkedlifedata.com/resource/pubmed/id/16987935
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0184511,
umls-concept:C0185117,
umls-concept:C0332281,
umls-concept:C0431085,
umls-concept:C0597032,
umls-concept:C0678222,
umls-concept:C0681842,
umls-concept:C1423842,
umls-concept:C1979963,
umls-concept:C2003903,
umls-concept:C2911684
|
pubmed:issue |
11
|
pubmed:dateCreated |
2006-10-17
|
pubmed:abstractText |
Studies aimed at elucidating the immunological and prognostic significance of HLA-DR expression on breast carcinoma cells have yielded contradictory results. To expand on previous studies, we have investigated the associations of tumor cell expression of HLA-DR and its related co-chaperones, invariant chain (Ii) and HLA-DM, with infiltrating inflammatory cells, in situ cytokine mRNA levels and prognosis and outcome in 112 breast carcinoma patients with a median follow-up of 59 months. While the majority of HLA-DR+ tumors co-express Ii, only a minority express HLA-DM. Tumor cell expression of HLA-DR and co-chaperones positively associated with both infiltrating CD4+ and CD8+ T-cell subsets (P < 0.01). Expression of HLA-DR and Ii associated with decreased estrogen receptor alpha levels and younger age at diagnosis, suggesting a role for hormones in the control of HLA class II expression in breast carcinoma. Patients with DR+Ii+DM- tumors had markedly decreased recurrence-free and disease-specific survival as compared with patients with DR+Ii+DM+ tumors (P < 0.05) and HLA-DR/co-chaperone expression was an independent predictor of survival by multivariate Cox regression analysis, controlling for standard prognostic indicators. Tumors that co-express HLA-DR, Ii and HLA-DM have increased levels of IFN-gamma, IL-2 and IL-12 mRNA, suggesting improved survival of patients with DR+Ii+DM+ tumors may be attributable to Th1-dominated immunity. We conclude that expression of determinants of the immune response by tumor cells may influence breast tumor progression and patient outcome.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0953-8178
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1591-602
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:16987935-Breast Neoplasms,
pubmed-meshheading:16987935-Carcinoma,
pubmed-meshheading:16987935-Disease-Free Survival,
pubmed-meshheading:16987935-Female,
pubmed-meshheading:16987935-HLA-D Antigens,
pubmed-meshheading:16987935-HLA-DR Antigens,
pubmed-meshheading:16987935-Humans,
pubmed-meshheading:16987935-Th1 Cells
|
pubmed:year |
2006
|
pubmed:articleTitle |
Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.
|
pubmed:affiliation |
Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John's, Newfoundland, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|